




Instance: composition-en-3a2e83e300727740331b28eb7f2593e4
InstanceOf: CompositionUvEpi
Title: "Composition for cotellic Package Leaflet"
Description:  "Composition for cotellic Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/15/1048/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp3a2e83e300727740331b28eb7f2593e4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cotellic"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Cotellic is and what it is used for </li>
<li>What you need to know before you take Cotellic </li>
<li>How to take Cotellic </li>
<li>Possible side effects </li>
<li>How to store Cotellic </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What cotellic is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What cotellic is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Cotellic is 
Cotellic is an anti-cancer medicine that contains the active substance cobimetinib.  </p>
<p>What Cotellic is used for 
Cotellic is used to treat adult patients with a type of skin cancer called melanoma, that has spread to 
other parts of the body or cannot be removed by surgery. 
* It is used in combination with another anti-cancer medicine called vemurafenib.<br />
* It can only be used in patients whose cancer has a change (mutation) in a protein called 
 BRAF . Before starting treatment, your doctor will test for this mutation. This change may 
have led to the development of melanoma.  </p>
<p>How Cotellic works 
Cotellic targets a protein called  MEK  that is important in controlling cancer cell growth. When 
Cotellic is used in combination with vemurafenib (which targets the changed  BRAF  protein), it 
further slows down or stops the growth of your cancer. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take cotellic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take cotellic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Cotellic: 
* if you are allergic to cobimetinib or any of the other ingredients of this medicine (listed in 
section 6). 
If you are not sure, talk to your doctor, pharmacist or nurse before taking Cotellic. </p>
<p>Warnings and precautions 
Talk to your doctor, pharmacist or nurse before taking Cotellic if you have: </p>
<ul>
<li>
<p>Bleeding 
Cotellic can cause severe bleeding, especially in your brain or stomach (see also  Severe bleeding  in 
Section 4). Tell your doctor straight away if you have any unusual bleeding or any of these symptoms: 
headaches, dizziness, feeling weak, blood in the stools or black stools and vomiting blood.   </p>
</li>
<li>
<p>Eye problems 
Cotellic can cause eye problems (see also  Eye (vision) problems  in Section 4). Tell your doctor 
straight away if you get the following symptoms: blurred vision, distorted vision, partly missing 
vision, or any other changes to your sight during treatment. Your doctor should examine your eyes if 
you have any new or worsening problems with your sight while you are taking Cotellic. </p>
</li>
<li>
<p>Heart problems 
Cotellic can lower the amount of blood pumped by your heart (see also  Heart problems  in 
Section 4). Your doctor should do tests before and during your treatment with Cotellic to check how 
well your heart can pump blood. Tell your doctor straight away if it feels like your heart is pounding, 
racing or beating unevenly, or if you experience dizziness, lightheadedness, shortness of breath, 
tiredness, or swelling in the legs.  </p>
</li>
<li>
<p>Liver problems 
Cotellic can increase the amount of some liver enzymes in your blood during treatment. Your doctor 
will do blood tests to check these amounts and monitor how well your liver is working.   </p>
</li>
<li>
<p>Muscle problems 
Cotellic can cause increased levels of creatine phosphokinase, an enzyme that is found mainly in the 
muscle, heart, and brain. This can be a sign of muscle damage (rhabdomyolysis) (see also  Muscle 
problems  in Section 4). Your doctor will do blood tests to monitor for this. Tell your doctor straight 
away if you get any of these symptoms: muscle aches, muscle spasms, weakness, or dark- or red-
coloured urine.  </p>
</li>
<li>
<p>Diarrhoea 
Tell your doctor straight away if you get diarrhoea. Severe diarrhoea can cause loss of body fluid 
(dehydration). Follow your doctor s instructions for what to do to help prevent or treat diarrhoea. </p>
</li>
</ul>
<p>Children and adolescents 
Cotellic is not recommended for children and adolescents. The safety and efficacy of Cotellic in 
people younger than 18 years old have not been established. </p>
<p>Other medicines and Cotellic 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This is because Cotellic can affect the way some other medicines work. Also, some other 
medicines can affect the way Cotellic works. </p>
<p>Talk to your doctor before taking Cotellic if you are taking: </p>
<p>Medicine<br />
Purpose of the medicine 
itraconazole, clarithromycin, erythromycin, 
telithromycin, voriconazole, rifampicin, 
posaconazole, fluconazole, miconazole 
for some fungal and bacterial infections 
ritonavir, cobicistat, lopinavir, delavirdine, 
amprenavir, fosamprenavir<br />
for HIV infection 
telaprevir 
for hepatitis C 
nefadozone 
for depression 
amiodarone 
for an uneven heartbeat 
diltiazem, verapamil 
for high blood pressure<br />
imatinib 
for cancer 
carbamazepine, phenytoin 
for fits (seizures) 
St John s Wort 
a herbal medicine, used to treat depression. 
This is available without prescription. </p>
<p>Cotellic with food and drink 
Avoid taking Cotellic with grapefruit juice. This is because it could increase the amount of Cotellic in 
your blood. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. 
* Cotellic is not recommended during pregnancy - although the effects of Cotellic have not been 
studied in pregnant women, it may cause permanent harm or birth defects to an unborn baby.<br />
<em> If you become pregnant during treatment with Cotellic or in the 3 months after your last dose, 
tell your doctor straight away. <br />
</em> It is not known if Cotellic passes into breast milk. Your doctor will discuss with you the benefits 
and risks of taking Cotellic, if you are breast-feeding.  </p>
<p>Contraception 
Women of childbearing potential should use two effective methods of contraception, such as a 
condom or other barrier method (with spermicide, if available) during treatment and for at least 
3 months after treatment has finished. Ask your doctor about the best contraception for you. </p>
<p>Driving and using machines 
Cotellic can affect your ability to drive or use machines. Avoid driving or using machines if you have 
problems with your vision or other problems that might affect your ability e.g. if you feel dizzy or 
tired. Talk to your doctor if you are not sure.  </p>
<p>Cotellic contains lactose and sodium 
The tablets contain lactose (a type of sugar). If you have been told by your doctor that you have an 
intolerance to some sugars, talk to your doctor before taking this medicine. </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free .   </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take cotellic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take cotellic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.  </p>
<p>How much to take 
The recommended dose is 3 tablets (a total of 60 mg) once a day.<br />
<em> Take the tablets every day for 21 days (called a  treatment period ).<br />
</em> After the 21 days, do not take any Cotellic tablets for 7 days. During this 7 day break in Cotellic 
treatment, you should keep taking vemurafenib as told by your doctor. 
* Start your next Cotellic 21 day treatment period after the 7 day break. 
* If you get side effects, your doctor may decide to lower your dose, stop treatment temporarily or 
permanently. Always take Cotellic exactly as your doctor or pharmacist has told you. </p>
<p>Taking the medicine 
* Swallow the tablets whole with water. 
* Cotellic can be taken with or without food.  </p>
<p>If you are sick 
If you are sick (vomit) after taking Cotellic, do not take an extra dose of Cotellic on that day. Continue 
to take Cotellic as normal, the next day.   </p>
<p>If you take more Cotellic than you should 
If you take more Cotellic than you should, talk to a doctor straight away. Take the medicine package 
and this leaflet with you.<br />
If you forget to take Cotellic 
* If it is more than 12 hours before your next dose, take the missed dose as soon as you 
remember.<br />
* If it is less than 12 hours before your next dose, skip the missed dose. Then take the next dose at 
the usual time. 
* Do not take a double dose to make up for a missed dose. </p>
<p>If you stop taking Cotellic 
It is important to keep taking Cotellic for as long as your doctor prescribes it.<br />
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get 
side effects your doctor may decide to lower your dose, stop treatment temporarily or permanently. </p>
<p>Please also refer to the Package Leaflet for vemurafenib, which is used in combination with Cotellic. </p>
<p>Serious side effects 
Tell your doctor straight away if you notice any of the side effects listed below or if these get worse 
during treatment. </p>
<p>Severe bleeding (common: may affect up to 1 in 10 people) 
Cotellic can cause severe bleeding, especially in your brain or stomach. Depending on the area of the 
bleeding, symptoms may include: 
* headaches, dizziness, or weakness 
* vomiting blood 
* abdominal pain 
* red or black coloured stools. </p>
<p>Eye (vision) problems (very common: may affect more than 1 in 10 people) 
Cotellic can cause eye problems. Some of these eye problems may be a result of  serous retinopathy<br />
(a build-up of fluid under the retina in the eye). Symptoms of serous retinopathy include:<br />
* blurred vision 
* distorted vision 
* partly missing vision 
* any other changes to your sight. </p>
<p>Heart problems (common: may affect up to 1 in 10 people) 
Cotellic can lower the amount of blood pumped by your heart. Symptoms may include:<br />
<em> feeling dizzy 
* feeling light-headed 
* feeling short of breath<br />
</em> feeling tired 
* feeling like your heart is pounding, racing or beating unevenly 
* swelling in the legs. </p>
<p>Muscle problems (uncommon: may affect up to 1 in 100 people) 
Cotellic can result in the breakdown of muscle (rhabdomyolysis), symptoms may include: 
* muscle aches 
* muscle spasms and weakness 
* dark- or red-coloured urine. </p>
<p>Diarrhoea (very common: may affect more than 1 in 10 people) 
Tell your doctor straight away if you get diarrhoea and follow your doctor s instructions for what to do 
to help prevent or treat diarrhoea. </p>
<p>Other side effects 
Tell your doctor, pharmacist or nurse if you notice any of the following side effects: </p>
<p>Very common (may affect more than 1 in 10 people) 
* increased skin sensitivity to sunlight 
* skin rash<br />
<em> feeling sick (nausea) 
* fever 
* chills 
* increased liver enzymes (shown in blood tests) <br />
</em> abnormal blood test results related to creatine phosphokinase, an enzyme found mainly in heart, 
brain and skeletal muscle 
* vomiting 
* skin rash with a flat discoloured area or raised bump like acne 
* high blood pressure 
* anaemia (a low level of red blood cells) 
* bleeding 
* abnormal thickening of the skin 
* swelling usually in the legs (oedema peripheral) 
itchy or dry skin. <br />
Common (may affect up to 1 in 10 people) 
* some types of skin cancer such as basal cell carcinoma, cutaneous squamous cell carcinoma and 
keratoacanthoma 
* dehydration, when your body does not have enough fluid 
* decreased levels of phosphate or sodium (shown in blood tests) 
* increased sugar level (shown in blood tests) 
* increased liver pigment (called  bilirubin ) in the blood. Signs include yellowing of the skin or 
eyes 
* inflammation of the lungs that may cause difficulty breathing, and can be life-threatening 
(called  pneumonitis ). </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store cotellic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store cotellic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>Keep this medicine out of the sight and reach of children. </li>
<li>Do not take this medicine after the expiry date which is stated on the blister and the carton after 
EXP. The expiry date refers to the last day of that month. </li>
<li>This medicine does not require any special storage conditions. </li>
<li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist 
how to throw away medicines you no longer use. These measures will help to protect the 
environment. </li>
</ul> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Cotellic contains 
* The active substance is cobimetinib. Each film-coated tablet contains cobimetinib hemifumarate 
equivalent to 20 mg cobimetinib. 
* The other ingredients are (see Section 2  Cotellic contains lactose and sodium ):<br />
  lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium 
stearate in the tablet core; and 
  polyvinyl alcohol, titanium dioxide, macrogol and talc in the film-coating.  </p>
<p>What Cotellic looks like and contents of the pack 
Cotellic film-coated tablets are white, round with  COB  debossed on one side. One pack size is 
available: 63 tablets (3 blisters of 21 tablets). </p>
<p>Marketing Authorisation Holder 
Roche Registration GmbH<br />
Emil-Barell-Strasse 1 
79639 Grenzach-Wyhlen 
Germany </p>
<p>Manufacturer 
Roche Pharma AG 
Emil-Barell-Strasse 1 
79639 Grenzach-Wyhlen 
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien<br />
N.V. Roche S.A.<br />
T l/Tel: +32 (0) 2 525 82 Lietuva<br />
UAB  Roche Lietuva <br />
Tel: +370 5 2546   </p>
<p>: +359 2 818 44 Luxembourg/Luxemburg<br />
(Voir/siehe Belgique/Belgien)<br />
 esk  republika<br />
Roche s. r. o.<br />
Tel: +420 - 2 20382Magyarorsz g<br />
Roche (Magyarorsz g) Kft.<br />
Tel: +36 - 1 279 4Danmark<br />
Roche Pharmaceutical A/S<br />
Tlf: +45 - 36 39 99 Malta<br />
(see Ireland)<br />
Deutschland<br />
Roche Pharma AG<br />
Tel: +49 (0) 7624 Nederland<br />
Roche Nederland B.V.<br />
Tel: +31 (0) 348 438Eesti<br />
Roche Eesti O <br />
Tel: + 372 - 6 177 Norge<br />
Roche Norge AS<br />
Tlf: +47 - 22 78 90  <br />
Roche (Hellas) A.E.<br />
 : +30 210 61 66  sterreich<br />
Roche Austria GmbH<br />
Tel: +43 (0) 1 27Espa a<br />
Roche Farma S.A.<br />
Tel: +34 - 91 324 81 Polska<br />
Roche Polska Sp.z o.o.<br />
Tel: +48 - 22 345 18 France<br />
Roche<br />
T l: +33 (0) 1 47 61 40 Portugal<br />
Roche Farmac utica Qu mica, Lda<br />
Tel: +351 - 21 425 70 Hrvatska<br />
Roche d.o.o.<br />
Tel: +385 1 4722 Rom nia<br />
Roche Rom nia S.R.L.<br />
Tel: +40 21 206 47 Ireland<br />
Roche Products (Ireland) Ltd.<br />
Tel: +353 (0) 1 469 0Slovenija<br />
Roche farmacevtska dru ba d.o.o.<br />
Tel: +386 - 1 360 26  sland<br />
Roche Pharmaceuticals A/S<br />
c/o Icepharma hf<br />
S mi: +354 540 8Slovensk  republika<br />
Roche Slovensko, s.r.o.<br />
Tel: +421 - 2 52638Italia<br />
Roche S.p.A.<br />
Tel: +39 - 039 2Suomi/Finland<br />
Roche Oy<br />
Puh/Tel: +358 (0) 10 554 K <br />
 . .  &amp;    .<br />
 : +357 - 22 76 62 Sverige<br />
Roche AB<br />
Tel: +46 (0) 8 726 1Latvija<br />
Roche Latvija SIA<br />
Tel: +371 - 6 7039United Kingdom (Northern Ireland) <br />
Roche Products (Ireland) Ltd.<br />
Tel: +44 (0) 1707 366This leaflet was last revised in {MM/YYYY} </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-3a2e83e300727740331b28eb7f2593e4
InstanceOf: CompositionUvEpi
Title: "Composition for cotellic Package Leaflet"
Description:  "Composition for cotellic Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/15/1048/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp3a2e83e300727740331b28eb7f2593e4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cotellic"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Cotellic 
3. Sådan skal du tage Cotellic 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er Cotellic? 
Cotellic er et lægemiddel mod kræft og indeholder det aktive stof cobimetinib. </p>
<p>Hvad bruges Cotellic til? 
Cotellic bruges til at behandle voksne patienter med en bestemt form for hudkræft, melanom, som har 
spredt sig til andre dele af kroppen eller ikke kan fjernes ved en operation. </p>
<ul>
<li>
<p>Det bruges sammen med et andet lægemiddel mod kræft, der hedder vemurafenib.  </p>
</li>
<li>
<p>Det kan kun bruges af patienter, hvis kræftsygdom har en ændring (mutation) i et protein, der 
kaldes BRAF. Før du begynder behandling, vil lægen undersøge, om du har denne mutation. 
Denne mutation kan være skyld i melanomet.  </p>
</li>
</ul>
<p>Hvordan virker Cotellic? 
Cotellic virker på et protein, der kaldes MEK. Dette protein har stor betydning for kontrollen af 
kræftcellernes vækst. Når Cotellic tages sammen med vemurafenib (som virker på det muterede 
BRAF-protein), vil det yderligere nedsætte eller stoppe væksten af kræftcellerne. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  cotellic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  cotellic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Cotellic: </p>
<ul>
<li>hvis du er allergisk over for cobimetinib eller et af de øvrige indholdsstoffer i medicinen 
(angivet i punkt 6). </li>
</ul>
<p>Hvis du ikke er sikker, skal du kontakte lægen, apotekspersonalet eller sundhedspersonalet, inden du 
tager Cotellic. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sundhedspersonalet, før du tager Cotellic, hvis du har 
problemer med </p>
<ul>
<li>
<p>Blødning 
Cotellic kan forårsage svær blødning, især i hjernen eller maven (se også "Svær blødning" i afsnit 4). 
Du skal straks kontakte lægen, hvis du oplever enhver usædvanlig blødning eller nogle af disse 
symptomer: hovedpine, svimmelhed, følelse af svaghed, blod i afføringen eller sort afføring og 
opkastning af blod. </p>
</li>
<li>
<p>Øjenproblemer 
Cotellic kan forårsage problemer med øjnene (Se også "Problemer med øjnene (synet)" i afsnit 4).<br />
Du skal straks kontakte lægen, hvis du får følgende symptomer: sløret syn, forvrænget syn, 
indskrænket synsfelt eller andre ændringer i dit syn under behandlingen. Lægen skal undersøge dine 
øjne, hvis du får nye problemer eller forværring af dit syn under behandling med Cotellic. </p>
</li>
<li>
<p>Hjerteproblemer 
Cotellic kan svække hjertets pumpeevne (se også "Hjerteproblemer" i afsnit 4). Lægen skal lave 
undersøgelser for at vurdere hjertets pumpeevne før og under din behandling med Cotellic. Du skal 
straks kontakte lægen, hvis du føler, at dit hjerte slår hårdere, hurtigere eller uregelmæssigt, eller hvis 
du oplever svimmelhed, stakåndethed, træthed eller hævede ben. </p>
</li>
<li>
<p>Leverproblemer 
Cotellic kan medføre forhøjede niveauer af nogle leverenzymer i blodet under behandlingen. Lægen 
vil tage blodprøver for at undersøge disse stigninger for at holde øje med din leverfunktion.  </p>
</li>
<li>
<p>Muskelproblemer 
Cotellic kan forårsage forhøjede niveauer af kreatinkinase, som er et enzym, der hovedsageligt findes i 
muskler, hjerte og hjerne. Dette kan være et tegn på muskelbeskadigelse (rabdomyolyse) (se 
også "Muskelproblemer" i afsnit 4). Din læge vil tage blodprøver for at monitorere dette. Du skal 
straks kontakte lægen, hvis du oplever nogle af disse symptomer: muskelømhed, muskelkramper, 
svaghed eller mørk eller rødfarvet urin.   </p>
</li>
<li>
<p>Diarré 
Fortæl straks lægen, hvis du får diarré. Svær diarré kan forårsage væsketab (dehydrering). Følg lægens 
anvisning om, hvordan diarréen kan forhindres eller behandles. </p>
</li>
</ul>
<p>Børn og unge<br />
Det frarådes at bruge Cotellic til børn og unge. Cotellics sikkerhed og virkning hos personer under år er ikke klarlagt. </p>
<p>Brug af anden medicin sammen med Cotellic 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. 
Det er vigtigt, fordi Cotellic kan påvirke virkningen af anden medicin, og anden medicin kan påvirke 
virkningen af Cotellic. </p>
<p>Kontakt lægen, inden du tager Cotellic, hvis du får: </p>
<p>Medicin<br />
Medicinens formål 
itraconazol, clarithromycin, erythromycin, 
telithromycin, voriconazol, rifampicin, 
posaconazol, fluconazol, miconazol 
for bestemte svampe- og bakterie-
infektioner 
ritonavir, cobicistat, lopinavir, delavirdin, 
amprenavir, fosamprenavir<br />
for HIV-infektion 
telaprevir 
for hepatitis C 
nefadozon 
for depression 
amiodaron 
for uregelmæssig hjerterytme 
diltiazem, verapamil 
for højt blodtryk 
imatinib 
for kræft 
carbamazepin, phenytoin 
for kramper<br />
perikon 
naturmedicin for depression. Kræver ikke 
recept. </p>
<p>Brug af Cotellic sammen med mad og drikke 
Undgå at drikke grapefrugtjuice, så længe du tager Cotellic. Det kan øge mængden af Cotellic i blodet. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge lægen eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<ul>
<li>
<p>Det frarådes at tage Cotellic under graviditet - selvom Cotellic ikke er undersøgt hos gravide 
kvinder, kan det muligvis skade det ufødte barn og forårsage misdannelser.  </p>
</li>
<li>
<p>Hvis du bliver gravid, mens du er i behandling med Cotellic eller inden for 3 måneder efter din 
sidste dosis, skal du straks kontakte lægen.   </p>
</li>
<li>
<p>Det vides ikke, om Cotellic udskilles i mælken hos mennesker. Hvis du ammer, vil lægen snakke 
med dig om fordele og risici ved at tage Cotellic.  </p>
</li>
</ul>
<p>Prævention 
Kvinder, der kan få børn, bør bruge 2 forskellige former for sikker prævention, såsom kondom eller 
andre barrieremetoder (med sæddræbende middel, hvis tilgængeligt), under behandlingen og i mindst 
3 måneder efter, behandlingen er afsluttet. Spørg lægen, hvilken prævention der er bedst for dig. </p>
<p>Trafik- og arbejdssikkerhed 
Cotellic kan påvirke din evne til at køre motorkøretøj  eller anvende maskiner. Undgå at køre 
motorkøretøj eller anvende maskiner, hvis du har problemer med synet eller andre problemer, som kan 
påvirke din evne, f.eks. hvis du er svimmel eller træt. Tal med lægen, hvis du er usikker. </p>
<p>Cotellic indeholder lactose og natrium 
Tabletterne indeholder lactose (en sukkerart). Kontakt lægen, inden du tager denne medicin, hvis 
lægen har fortalt dig, at du ikke tåler visse former for sukker. </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. tablet, det vil sige, den er i det 
væsentlige natrium-fri. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage cotellic"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage cotellic"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid medicinen nøjagtig efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den sædvanlige dosis er 
Den anbefalede dosis er 3 tabletter (i alt 60 mg) 1 gang dagligt.  </p>
<ul>
<li>
<p>Tag tabletterne hver dag i 21 dage (kaldes en behandlingsperiode).  </p>
</li>
<li>
<p>Efter de 21 dage skal du ikke tage Cotellic i 7 dage. Mens du holder denne 7 dages pause med 
Cotellic, skal du fortsætte behandlingen med vemurafenib som foreskrevet af lægen. </p>
</li>
<li>
<p>Start næste behandlingsperiode (21 dage) med Cotellic efter 7 dages pausen. </p>
</li>
<li>
<p>Hvis du får bivirkninger, kan lægen beslutte at nedsætte dosis eller afbryde behandlingen 
midlertidigt eller permanent. Tag altid Cotellic præcist, som lægen foreskriver. </p>
</li>
</ul>
<p>Sådan tages medicinen: </p>
<ul>
<li>
<p>Synk tabletten hel med vand. </p>
</li>
<li>
<p>Cotellic kan tages sammen med eller uden mad.  </p>
</li>
</ul>
<p>Hvis du kaster op 
Hvis du kaster op, efter du har taget Cotellic, skal du ikke tage en ny dosis Cotellic samme dag. Tag 
Cotellic igen næste dag, helt som du plejer. </p>
<p>Hvis du har taget for meget Cotellic 
Hvis du har taget flere Cotellic, end du skulle, skal du straks kontakte en læge. Tag medicinpakningen 
og denne indlægsseddel med. </p>
<p>Hvis du har glemt at tage Cotellic </p>
<ul>
<li>
<p>Hvis der er mere end 12 timer til næste dosis, skal du tage den glemte dosis, så snart du kommer i 
tanker om det. </p>
</li>
<li>
<p>Hvis der er mindre end 12 timer til næste dosis, skal du springe den glemte dosis over og tage 
næste dosis på det planlagte tidspunkt. </p>
</li>
<li>
<p>Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
</li>
</ul>
<p>Hvis du holder op med at tage Cotellic 
Det er vigtigt, at du bliver ved med at tage Cotellic lige så længe, lægen har ordineret det.<br />
Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget, du er i tvivl om.  </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. Hvis du 
får bivirkninger, kan lægen beslutte at nedsætte dosis eller afbryde behandlingen midlertidigt eller 
permanent. </p>
<p>Læs også indlægssedlen for vemurafenib, som du tager sammen med Cotellic. </p>
<p>Alvorlige bivirkninger 
Fortæl straks lægen, hvis du oplever en eller flere af bivirkningerne nedenfor, eller hvis den/disse 
forværres under behandlingen. </p>
<p>Svær blødning (almindelige: kan optræde hos op til 1 ud af 10 patienter) 
Cotellic kan give svær blødning, især i din hjerne eller mave. Afhængig af hvorhenne 
blødningen opstår, kan symptomer inkludere: 
• hovedpine, svimmelhed eller svaghed 
• opkastning af blod 
• mavesmerter 
• rød eller sortfarvet afføring </p>
<p>Øjenproblemer (syn) (meget almindelige: kan optræde hos flere end 1 ud af 10 patienter) 
Cotellic kan give øjenproblemer. Nogle af disse øjenproblemer kan skyldes ophobning af væske 
under nethinden i øjet (serøs retinopati). Symptomer af serøs retinopati kan være:<br />
• sløret syn 
• forvrænget syn 
• indskrænket synsfelt 
• andre ændringer i synet  </p>
<p>Hjerteproblemer (almindelige: kan optræde hos op til 1 ud af 10 patienter) 
Cotellic kan nedsætte hjertets pumpeevne. Symptomerne kan være:<br />
• svimmelhed 
• ør i hovedet 
• stakåndethed<br />
• træthed 
• følelse af, at hjertet banker hårdere, hurtigere eller uregelmæssigt 
• hævede ben </p>
<p>Muskelproblemer (ikke almindelige: kan optræde hos op til 1 ud af 100 patienter) 
Cotellic kan forårsage muskelbeskadigelse (rabdomyolyse). Symptomer kan omfatte: 
• muskelømhed 
• muskelkramper og svaghed 
• mørk eller rødfarvet urin </p>
<p>Diarré (meget almindelig: kan optræde hos flere end 1 ud af 10 patienter) 
Fortæl straks lægen, hvis du får diarré, og følg lægens anvisning om, hvordan diarréen kan 
forhindres eller behandles. </p>
<p>Andre bivirkninger 
Kontakt lægen, apotekspersonalet eller sundhedspersonalet, hvis du bemærker én eller flere af 
følgende bivirkninger: 
Meget almindelige (kan optræde hos flere end 1 ud af 10 patienter) 
• huden bliver mere følsom for sol<br />
• udslæt<br />
• kvalme 
• feber 
• kuldegysninger 
• forhøjede lever-enzymer (ses ved blodprøve)<br />
• unormale blodprøveresultater for kreatinkinase, som er et enzym, som hovedsageligt<br />
 findes i hjertet, hjernen og skeletmuskulaturen 
• opkastning 
• udslæt med flade misfarvede pletter eller udslæt, der kan ligne bumser som akne 
• forhøjet blodtryk 
• anæmi (lavt antal røde blodlegemer) 
• blødning 
• unormal fortykkelse af huden 
• hævelse, sædvanligvis i benene (perifært ødem) 
• kløende eller tør hud 
• mundbetændelse eller mundsår, betændelse i slimhinderne (stomatitis) </p>
<p>Almindelige (kan optræde hos op til 1 ud af 10 patienter) </p>
<p>• visse former for hudkræft såsom basalcellekræft, pladecellekræft og keratoakantom 
• dehydrering, hvor kroppen mangler væske 
• fald i fosfat- eller natriumværdier (ses ved blodprøve) 
• forhøjede sukkerværdier (ses ved blodprøve) 
• forhøjet bilirubin (leverpigment) i blodet. Symptomerne inkluderer gulfarvning af hud og øjne 
• irritation (inflammation) af vævet i lungerne, hvilket kan give vejrtrækningsbesvær og kan 
være livstruende (kaldes "pneumonitis") </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>
<p>Opbevar lægemidlet utilgængeligt for børn. </p>
</li>
<li>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisterpakningen og kartonen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
</li>
<li>
<p>Dette lægemiddel kræver ikke særlige opbevaringsforhold. </p>
</li>
<li>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet eller skraldespanden. </p>
</li>
</ul> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cotellic indeholder: </p>
<ul>
<li>
<p>Aktivt indholdsstof: cobimetinib. Hver filmovertrukken tablet indeholder 
cobimetinibhemifumarat svarende til 20 mg cobimetinib. </p>
</li>
<li>
<p>Øvrige indholdsstoffer (se afsnit 2 "Cotellic indeholder lactose og natrium"): 
• lactosemonohydrat, mikrokrystallinsk cellulose, croscarmellosenatrium og  <br />
  magnesiumstearat i tabletkernen og<br />
• polyvinylalkohol, titandioxid, macrogol og talcum i filmovertrækket. </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Cotellic filmovertrukne tabletter er hvide og runde med “COB" præget på den ene side. Der findes én 
pakningsstørrelse: 63 tabletter (3 blistere med 21 tabletter). </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Roche Registration GmbH<br />
Emil-Barell-Strasse 1 
79639 Grenzach-Wyhlen 
Tyskland </p>
<p>Fremstiller 
Roche Pharma AG 
Emil-Barell-Strasse 1 
70Grenzach-Wyhlen 
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
N.V. Roche S.A. 
Tél/Tel: +32 (0) 2 525 82<br />
Lietuva 
UAB “Roche Lietuva" 
Tel: +370 5 2546 
България 
Рош България ЕООД 
Тел: +359 2 818 44<br />
Luxembourg/Luxemburg 
(Voir/siehe Belgique/Belgien) </p>
<p>Česká republika 
Roche s. r. o. 
Tel: +420 - 2 20382 
Magyarország 
Roche (Magyarország) Kft. 
Tel: +36 - 1 279 4 
Danmark 
Roche Pharmaceuticals A/S 
Tlf: +45 - 36 39 99<br />
Malta 
(see Ireland) </p>
<p>Deutschland 
Roche Pharma AG 
Tel: +49 (0) 7624<br />
Nederland 
Roche Nederland B.V. 
Tel: +31 (0) 348 438 
Eesti 
Roche Eesti OÜ 
Tel: + 372 - 6 177<br />
Norge 
Roche Norge AS 
Tlf: +47 - 22 78 90<br />
Ελλάδα 
Roche (Hellas) A.E.<br />
Τηλ: +30 210 61 66<br />
Österreich 
Roche Austria GmbH 
Tel: +43 (0) 1 27 
España 
Roche Farma S.A. 
Tel: +34 - 91 324 81<br />
Polska 
Roche Polska Sp.z o.o. 
Tel: +48 - 22 345 18<br />
France 
Roche 
Tél: +33  (0)1 47 61 40<br />
Portugal 
Roche Farmacêutica Química, Lda 
Tel: +351 - 21 425 70<br />
Hrvatska 
Roche d.o.o. 
Tel: + 385 1 47 22<br />
România 
Roche România S.R.L. 
Tel: +40 21 206 47<br />
Ireland 
Roche Products (Ireland) Ltd. 
Tel: +353 (0) 1 469 0 
Slovenija 
Roche farmacevtska družba d.o.o. 
Tel: +386 - 1 360 26<br />
Ísland<br />
Roche Pharmaceuticals A/S 
c/o Icepharma hf 
Sími: +354 540 8 
Slovenská republika<br />
Roche Slovensko, s.r.o. 
Tel: +421 - 2 52638 
Italia 
Roche S.p.A. 
Tel: +39 - 039 2Suomi/Finland 
Roche Oy<br />
Puh/Tel: +358 (0) 10 554<br />
Kύπρος<br />
Γ.Α.Σταμάτης &amp; Σια Λτδ. 
Τηλ: +357 - 22 76 62<br />
Sverige 
Roche AB 
Tel: +46 (0) 8 726 1 
Latvija 
Roche Latvija SIA 
Tel: +371 - 6 7039 
United Kingdom (Nothern Ireland) 
Roche Products (Ireland) Ltd. 
Tel: +44 (0) 1707 366 </p>
<p>Denne indlægsseddel blev senest ændret &lt;{MM/ÅÅÅÅ}&gt; &lt;{måned ÅÅÅÅ}.&gt; </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-3a2e83e300727740331b28eb7f2593e4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cotellic Package Leaflet for language en"
Description: "ePI document Bundle for cotellic Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-3a2e83e300727740331b28eb7f2593e4"
* entry[0].resource = composition-en-3a2e83e300727740331b28eb7f2593e4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3a2e83e300727740331b28eb7f2593e4"
* entry[=].resource = mp3a2e83e300727740331b28eb7f2593e4
                            
                    
Instance: bundlepackageleaflet-da-3a2e83e300727740331b28eb7f2593e4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cotellic Package Leaflet for language da"
Description: "ePI document Bundle for cotellic Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-3a2e83e300727740331b28eb7f2593e4"
* entry[0].resource = composition-da-3a2e83e300727740331b28eb7f2593e4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3a2e83e300727740331b28eb7f2593e4"
* entry[=].resource = mp3a2e83e300727740331b28eb7f2593e4
                            
                    



Instance: mp3a2e83e300727740331b28eb7f2593e4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Cotellic 20 mg film-coated tablets"
Description: "Cotellic 20 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/15/1048/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Cotellic 20 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 3a2e83e300727740331b28eb7f2593e4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "cotellic"

* status = #current
* mode = #working

* title = "List of all ePIs associated with cotellic"

* subject = Reference(mp3a2e83e300727740331b28eb7f2593e4)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#cotellic "cotellic"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-3a2e83e300727740331b28eb7f2593e4) // cotellic en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-3a2e83e300727740331b28eb7f2593e4) // cotellic da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-3a2e83e300727740331b28eb7f2593e4
InstanceOf: List
Description: "ePI document List for cotellic Package Leaflets"

* insert 3a2e83e300727740331b28eb7f2593e4ListRuleset
    